Genelux Adds Biotech Veteran Sidransky to Board
Ticker: GNLX · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1231457
| Field | Detail |
|---|---|
| Company | Genelux Corp (GNLX) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, governance, personnel
TL;DR
Genelux adds Dr. Sidransky to its board, bringing biotech expertise.
AI Summary
On September 23, 2024, Genelux Corporation announced the election of Dr. David L. Sidransky to its Board of Directors, effective immediately. Dr. Sidransky brings extensive experience in the biotechnology and pharmaceutical sectors, including his role as Chairman and CEO of Cyl-Vita, Inc. and his professorship at Johns Hopkins University School of Medicine.
Why It Matters
The addition of a seasoned director like Dr. Sidransky could signal strategic growth or new directions for Genelux, potentially impacting its future development and market position.
Risk Assessment
Risk Level: low — This filing primarily concerns a board appointment, which is a routine corporate governance event with limited immediate financial risk.
Key Players & Entities
- Genelux Corporation (company) — Registrant
- Dr. David L. Sidransky (person) — Newly elected Director
- Cyl-Vita, Inc. (company) — Dr. Sidransky's previous role
- Johns Hopkins University School of Medicine (company) — Dr. Sidransky's professorship
FAQ
When was Dr. David L. Sidransky elected to the Board of Directors?
Dr. David L. Sidransky was elected to the Board of Directors effective September 23, 2024.
What is Dr. Sidransky's current academic affiliation?
Dr. Sidransky is a Professor at Johns Hopkins University School of Medicine.
What is Dr. Sidransky's prior executive experience mentioned?
Dr. Sidransky served as Chairman and CEO of Cyl-Vita, Inc.
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
In which state is Genelux Corporation incorporated?
Genelux Corporation is incorporated in Delaware.
Filing Stats: 403 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2024-10-03 17:30:32
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share GNLX The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-039417.txt ( ) — 210KB
- gnlx-20240923.xsd (EX-101.SCH) — 3KB
- gnlx-20240923_lab.xml (EX-101.LAB) — 33KB
- gnlx-20240923_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelux Corporation Date: October 3, 2024 By: /s/ Thomas Zindrick, J.D. Thomas Zindrick, J.D. President and Chief Executive Officer